Research indicates that aberrant expression or amplification of TOP2A is common in various malignancies, including breast, lung, and GC, correlating with poor prognosis and resistance to chemotherapy (Li et al., 2022; Lee et al., 2023). This evidence concerns the gene TOP2A and gastric cancer.